Details, Fiction and Clinical trial recruitment for ABBV-744 study
In Segment C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Contributors will obtain treatment until eventually condition progression or the participants are not able to tolerate the study drugs.88 These preclinical studies deliver paradigms for long term clinical trials in AML, and u